Importantly, pharmacological targeting of NAT10 or DKK2 synergizes with anti–PD-1 therapy, providing a potential combinatorial strategy to overcome immunotherapy resistance in CRC. The gene discussed is NAT10; the disease is colorectal carcinoma.